TerraPower

TerraPower

Develops advanced nuclear reactors and isotopes

Overview

TerraPower develops advanced nuclear technologies to provide carbon-free energy and medical isotopes. The company works on next-generation reactors such as the Traveling Wave Reactor, Molten Chloride Fast Reactor, and sodium fast reactor. Its products generate electricity through fission in these next-gen designs, and the medical isotope work involves extracting isotopes like Actinium-225 for cancer treatment via partnerships (e.g., with Radiopharm). TerraPower generates revenue through technology licensing, partnerships, and supply agreements, serving utilities, government agencies, and medical institutions. The company differentiates itself by pursuing a diverse portfolio of reactor technologies and by combining power generation with medical isotope applications, complemented by collaborations and licensing to bring technologies to market. Its goal is to provide scalable, carbon-free energy while addressing medical needs through isotope production and new reactor deployments.

About TerraPower

Simplify's Rating
Why TerraPower is rated
C
Rated B on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

Industrial & Manufacturing

Energy

Healthcare

Company Size

1,001-5,000

Company Stage

Late Stage VC

Total Funding

$1.6B

Headquarters

Bellevue, Washington

Founded

2008

Get referred to TerraPower

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Meta deal secures up to eight Natrium plants by 2035, first two online in 2032
  • HD Hyundai partnership establishes scalable supply chain for serial production of reactor components
  • UK GDA Step 1 launch marks first regulatory progress outside US, enabling €3B European project

What critics are saying

  • Wyoming plant missing 2030 commissioning triggers $1.2B Meta contract cancellation within 12–18 months
  • UK ONR rejects Natrium GDA due to unresolved sodium-coolant safety issues, halting $3B project in 9–15 months
  • GE-Hitachi IP dispute over core sodium-cooled reactor and molten-salt storage technology escalates to arbitration

What makes TerraPower unique

  • Natrium reactor uniquely pairs a 345MW sodium-cooled fast reactor with molten-salt energy storage
  • Storage system boosts output to 500MW during peak demand while maintaining stable baseload
  • Only advanced reactor design enabling flexible grid integration with fluctuating renewable resources

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1.6B

Above

Industry Average

Funded Over

7 Rounds

Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison
Coming Soon

Benefits

Health Insurance

Vision Insurance

Dental Insurance

Life Insurance

Disability Insurance

Parental Leave

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Relocation Assistance

Professional Development Budget

Conference Attendance Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
DataM Intelligence
Jul 16th, 2026
From refinery ruins to life sciences powerhouse: Philadelphia's Bellwether District attracts $450M biotech investment.

From refinery ruins to life sciences powerhouse: Philadelphia's Bellwether District attracts $450M biotech investment. Philadelphia's former oil refinery site is undergoing a major transformation into a next-generation life sciences and advanced manufacturing ecosystem. TerraPower Isotopes, backed by Bill Gates-founded TerraPower, plans to invest $450 million in a new medical isotope production facility, signaling growing momentum for brownfield redevelopment and biotech infrastructure investment in the United States. Editorial Review: Akshay Reddy Published on: Jul 16, 2026 Nuclear Medicine Radioisotopes Market Size, Share, Industry, Forecast and outlook (2026-2033) The transformation of legacy industrial assets into innovation-driven economic engines is accelerating across the United States. One of the most significant examples is unfolding in Philadelphia, where the former Philadelphia Energy Solutions (PES) refinery site is being redeveloped into a large-scale life sciences and advanced manufacturing district. The 1,300 acre property, now known as the Bellwether District, was once home to the largest oil refinery on the U.S. East Coast. Following a catastrophic refinery explosion in 2019 that led to the facility's closure and bankruptcy, developers initiated one of the nation's most ambitious brownfield redevelopment projects. A major milestone in the site's evolution has emerged with TerraPower Isotopes' commitment to invest approximately $450 million in a state-of-the-art manufacturing facility dedicated to producing medical isotopes used in advanced cancer therapies. The facility is expected to serve the growing global demand for precision oncology treatments and radiopharmaceutical innovation. Strategic shift from fossil fuels to biotechnology. The Bellwether District represents a broader shift occurring across industrial economies, where underutilized energy and manufacturing assets are being repurposed to support high-growth sectors such as biotechnology, life sciences, clean technology, and advanced manufacturing. Developers have spent years dismantling aging refinery infrastructure, removing hundreds of storage tanks, decommissioning pipelines, and remediating environmental risks to prepare the site for modern industrial tenants. These efforts have significantly improved the site's attractiveness to technology-driven manufacturers and institutional investors. Industry analysts note that large-scale redevelopment projects offer a unique opportunity to combine sustainability objectives with economic growth strategies. Instead of developing greenfield locations, companies can leverage existing transportation networks, utility infrastructure, and workforce availability while supporting environmental restoration goals. Explore the Nuclear Medicine Radioisotopes Market Report Discover exclusive insights into Nuclear Medicine Radioisotopes Market growth, emerging radiopharmaceutical innovations, key players, regional opportunities, and future demand trends driving the global nuclear medicine radioisotopes industry through 2033. Request a Nuclear Medicine Radioisotopes Market Sample Report. Why life sciences companies are choosing Philadelphia. Philadelphia continues to strengthen its position as one of North America's leading life sciences ecosystems. The region benefits from a deep talent pool, world-class research institutions, major healthcare systems, and established pharmaceutical manufacturing capabilities. These advantages have helped attract significant biotech investments despite broader industry challenges. For TerraPower Isotopes, access to specialized scientific talent, logistics infrastructure, and proximity to research organizations played a critical role in site selection. The project is expected to create hundreds of high-skilled jobs while supporting long-term innovation within the regional healthcare and biotechnology sectors. A blueprint for future industrial redevelopment. The Bellwether District redevelopment illustrates how former industrial sites can be repositioned as innovation campuses capable of supporting next-generation industries. Plans for the district include millions of square feet of manufacturing, research, logistics, and commercial space, with projections indicating substantial economic impact through job creation and tax revenue generation over the coming decade. As governments and private investors increasingly prioritize resilient supply chains, domestic pharmaceutical manufacturing, and sustainable infrastructure development, projects like Bellwether may become a model for future brownfield-to-biotech transformations worldwide. What is the Bellwether District in Philadelphia? The Bellwether District is a 1,300 acre redevelopment project built on the former Philadelphia Energy Solutions rfinery site. Following the refinery's closure after a 2019 explosion, the property is being transformed into a life sciences, advanced manufacturing, and innovation hub. The project gained significant momentum after TerraPower Isotopes announced a $450 million investment to establish a medical isotope manufacturing facility supporting cancer treatment development. News source: https://www.wsj.com/articles/burned-out-philadelphia-refinery-finds-new-life-as-life-sciences-hub-10fbbe26 Found it interesting? Email: [email protected] US: +1 877 441 4866 DataM Intelligence has 10,000+ research reports serving across 100+ countries

Predifi
Jun 23rd, 2026
TerraPower's $3B nuclear reactor project in UK: A European game changer.

TerraPower's $3B nuclear reactor project in UK: A European game changer. Predifi Marketing Agent AI-Powered Market Intelligence Technology Key points. * TerraPower, backed by Bill Gates, selects a UK site for a $3 billion, 345MW nuclear reactor. * The project aims to support UK decarbonization goals and create regional jobs. * Expected to serve as a model for future reactor installations across Europe. * Potential regulatory and public opposition poses underpriced risk. * Watch for UK government approvals and public sentiment shifts. In a bold move towards European nuclear energy expansion, TerraPower, the U.S. advanced nuclear company backed by Bill Gates, has chosen a site in north-east England for its first European next-generation nuclear reactor. This project, estimated to cost several billion pounds, is set to deliver a reactor with an electric capacity of 345 megawatts. The selection of this site, a former coal-fired power station, underscores a significant shift towards advanced nuclear technologies in the region. The stakes are high. This project is not just a step towards decarbonization but also a strategic move to enhance energy security in Europe. With the UK Department for Energy Security and Net Zero offering its support, and British energy utilities partnering in the venture, the project is poised to create a ripple effect across the continent. It is a testament to the growing global demand for clean energy solutions and the pivotal role advanced nuclear technology can play in meeting these needs. TerraPower, the U.S. advanced nuclear company founded by Bill Gates, has announced the selection of a site in north-east England for its first European sodium-cooled fast reactor and molten-salt energy storage project. The chosen location is a former coal-fired power station, now set to host a reactor with an electric capacity of approximately 345 megawatts. The total investment for this project is estimated to be in the several-billion-pound range. This initiative is developed in partnership with British energy utility companies and is supported by the UK government's Department for Energy Security and Net Zero. The project is expected to contribute significantly to the UK's decarbonization targets and is anticipated to create jobs in the region. TerraPower envisions this project as a template for exporting its reactor technology across Europe, potentially influencing energy policies and investment strategies in the region. The root cause of this development is the global push for decarbonization and enhanced energy security. TerraPower, recognizing the growing demand for clean energy solutions, seeks to expand its advanced nuclear technology internationally. This move is part of a causal chain that begins with the identification of the need for clean energy, followed by TerraPower's strategic decision to enter the European market, and culminating in the selection of a site in the UK. This project is a classic example of Keynesian multiplier dynamics, where initial investment in infrastructure leads to increased economic activity and job creation. However, an underpriced risk in this scenario is the potential for regulatory and public opposition to advanced nuclear projects in Europe, which could hinder the project's progress and broader adoption of similar technologies. The announcement of TerraPower's project is expected to trigger immediate repricing in the stocks of its partners and British energy utilities. This initial movement will likely be followed by shifts in European energy sector ETFs and bonds as investors reassess the region's nuclear energy landscape. The transmission mechanism here is straightforward: the project signals a significant investment in advanced nuclear technology, which could lead to a reevaluation of risk and return profiles in the European energy sector. Moreover, this development could spur cross-asset spillover effects, influencing not just equity and bond markets but also commodities like uranium, given the increased demand for nuclear fuel. The European nuclear energy expansion is likely to attract attention from investors and policymakers alike, leading to a recalibration of strategies in the energy sector. The success of TerraPower's project hinges on several key factors, including UK government approvals, public sentiment, and the project's adherence to environmental and safety standards. Investors and market participants should watch for updates on these fronts, as they will be critical in determining the project's trajectory and its impact on the European energy market. The single most important question remaining is whether this project will serve as a catalyst for broader adoption of advanced nuclear technologies in Europe, potentially reshaping the continent's energy landscape. Prediction markets related to European nuclear energy expansion, advanced nuclear technology adoption, and UK energy policy will show the most sensitivity to this development. The timeline for significant market movements will depend on project milestones, regulatory approvals, and public sentiment shifts. Major impact areas. * European nuclear energy ETFs85% * Uranium commodities72% * British energy utility stocks68% Predifi is an on-chain prediction market platform. Join the waitlist #technology #prediction-markets #market-analysis #terrapower #nuclear-energy #decarbonization #energy-security

Select Greater Philadelphia
May 26th, 2026
Connecting global innovators to Greater Philadelphia.

Connecting global innovators to Greater Philadelphia. The recent expansion of several global companies into its region was made possible by the dedicated work of the Select Greater Philadelphia team at the Chamber of Commerce for Greater Philadelphia. By coordinating regional partners and providing specialized support, the Select team ensured each business had the resources and connections required to establish successful operations in Philadelphia. Bonduelle Americas establishes new Growth Hub. Bonduelle Americas announced the Bonduelle Americas Growth Hub, marking the North American expansion of an over $2B global food company and one of France's most recognized household brands. The company projects the creation of over 100 corporate jobs in the region within three years. Select engaged a coalition of 25 regional partners, spanning real estate, legal services, food and beverage industry networks, anchor institutions, and more, to connect the company with the resources and relationships needed to hit the ground running. CTIBIOTECH lands North American headquarters at BioLabs Philadelphia. CTIBIOTECH, a French bioengineering company, today announced the establishment of a North American headquarters in Greater Philadelphia at BioLabs Philadelphia, a premier shared life sciences laboratory facility. The company projects the creation of 35 specialized biotech jobs in the region within three to five years. Select connected CTIBIOTECH's decision-makers with research partners, cold storage providers, legal counsel, accounting services, and real estate options, helping the company to develop significant business relationships in the region. TerraPower Isotopes' new $450M lab breaks ground. TerraPower Isotopes recently broke ground on a new radioisotope manufacturing facility in Philadelphia's Bellwether District. Announced by Governor Josh Shapiro in March, this $450 million project by HRP Group will produce cancer-fighting drugs and create at least 225 jobs within Pennsylvania's life sciences industry. Select supported TerraPower Isotopes throughout the site selection process, highlighting the region's competitive advantages for large-scale clinical and manufacturing investments. Vylor to Open Global Corporate Business Center The Commonwealth has secured a $7 million investment from future advanced seed and genetics company Vylor to open its Global Corporate Business Center in Pennsylvania. The company, which will be spun off from Corteva in the fourth quarter of 2026, will create a minimum of 130 new, high-paying jobs over the next five years. Select provided research support and a connection to the Philadelphia International Airport to help make the case for Greater Philadelphia.

Recently Posted Jobs

Sign up to get curated job recommendations

TerraPower is Hiring for 77 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →